Several Factors Play Role in Semaglutide Initiation for Obesity Without Diabetes
By Lori Solomon HealthDay Reporter
THURSDAY, Jan. 23, 2025 -- Sociodemographic, health care, and clinical factors are associated with receipt of semaglutide in those with obesity but without diabetes, according to a study published online Jan. 21 in JAMA Network Open.
Meghan I. Podolsky, from the Boston University School of Public Health, and colleagues explored factors associated with semaglutide initiation among commercially insured individuals with obesity but no diagnosed diabetes. The analysis included 97,456 adults with a first diagnosis of obesity (June 5, 2021, to July 1, 2022) identified from the Merative MarketScan Commercial Claims and Encounters Database.
The researchers found that 2.0 percent of individuals initiated semaglutide within six months of their initial obesity diagnosis. A random-forest model had an area under the receiver operating characteristic curve of 0.71 for predicting semaglutide initiation. In a Shapley Additive Explanations plot, the most important exposures identified were sex, use of antidepressants, and employer industry. In the logistic regression model of the top 20 factors, significant associations for semaglutide initiation included being female (adjusted odds ratio, 2.30), using certain medication classes including antidepressants (adjusted odds ratio, 1.62), and being covered by a point-of-service plan (adjusted odds ratio, 1.78).
"These findings suggest that insurance plan type and structure may be a crucial intervention point for improving equity in obesity treatment access," the authors write.
One author disclosed ties to Swiss Re and Johnson & Johnson.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted January 2025
Read this next
Risk of Obesity-Related Cancer Similar for GLP-1 Receptor Agonists and Bariatric Surgery
THURSDAY, May 15, 2025 -- Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may cut the risk of obesity-related cancer (ORC) in patients being treated for diabetes and...
Metabolic and Bariatric Surgery Increased in Adolescents From 2021 to 2023
WEDNESDAY, May 14, 2025 -- Despite the approval of second-generation antiobesity medications, metabolic and bariatric surgery (MBS) use among U.S. adolescents increased from 2021...
Preoperative SGLT2 Inhibitor Users Have Increased Risk for Postoperative Euglycemic Ketoacidosis
TUESDAY, May 13, 2025 -- Patients using sodium-glucose cotransporter 2 inhibitors (SGLT2i) preoperatively have a slightly increased risk for postoperative euglycemic ketoacidosis...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.